Cancer is the second greatest cause of death in affluent nations and one of the biggest global problems. Cancer is the second leading cause of mortality in wealthy countries. 1 The discovery of novel, effective cancer medicines is a key objective in medicinal chemistry because of the toxicity and drug resistance. Furthermore, drug discovery and development programs have been laid off in large numbers in recent years due to the pharmaceutical industry's inability to sustain its level of profitability. One of the main strategies for finding new medications is still the chemical modification of a promising lead compound. ^{2, 3} Heterocyclic compounds are important in biology and chemistry. Their therapeutic, chemical, and physical characteristics are distinct. ^{4, 5} A computer simulation method called molecular docking is used to identify potential drug candidates that can attach to a protein's active site. This study examined the anticancer properties of five heterocyclic compounds using molecular docking with PyRX 0.8 and MZ dock software. The main focus was on the co-crystallized human cyclin-dependent kinase 2 (cdk2) complex with the oncoprotein PDGFRA 6JQI (Figure 4) and receptor 3EZV, CDK-2 with indazole inhibitor nine bound at its active site The toxicity of the lead molecule was also assessed using PROTOX software. After redocking with conventional ligands, SWISS ADME software computed bioavailability and confirmed the results. According to the findings, substances like ethyl 2,3-dihydro-1h-indole-2-carboxylate, [(4-ethoxyphenyl) methyl] Phenyl (2s, 3r, 4r, 5s, 6r) -n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl) amino] phenyl] benzamide with -2-[4-chloro-3-] 4-[(4-methylpiperazin-1-yl) methyl], 6methylsulfanyl oxane-3,4,5-triol, and the well-known drug imatinib was used for comparison. The SWISS ADME data showed that the selected lead compounds had favourable ADME profiles. Despite the need for further research, these results suggest that the lead compounds could be beneficial additions to medicine. To confirm the safety and effectiveness of these heterocyclics as potential therapeutic agents, more investigation is needed, especially in vivo studies.6, 7

For the present study, the employed software was PyRX 0.8 and MZ DOCK⁸free versions, Biovia Discovery Studio (DS) visualizer. The research utilized internet resources, including the NCBI PubChem database ^{8, 9, 10}, the Protein Data Bank (RCSB PDB), and SWISS ADME. And PROTOX, a virtual lab for the prediction of toxicities of small molecules.

To identify possible ligand binding modes with validated therapeutic proteins, researchers frequently employ the molecular docking approach. It is a technique that has proven effective in examining how different ligands interact with proteins. The X-ray crystal structures of the receptors 6JOI and 3EZV, ^{15, 16} which, which are essential for many drug studies, were used in the current study to perform molecular docking 17. Five chemical compounds, including currently available drugs with oxygen or nitrogen atoms in their chemical structure, were examined in silico against two receptors, 3EZV and 6JOI, using two distinct docking programs, PyRX docking and MZ-DOCK. The potential of these compounds is demonstrated by imatinib, the standard used to validate the methodology. Ethyl 2,3-dihydro-1h-indole-2-carboxylate (-10.3 MZ dock-3EZV, -8.6 PyRX-3EZV, -9.6 MZ-DOCK 6JOI) is one of the promising candidates chosen for additional research. It shows promise in comparison to Indinavir (-10.3 MZ dock-3EZV, -10.2 PyRX-3EZV, -10.7 MZ-DOCK 6JOI) (Table 1). According to Lipinski's rule, the Swiss-ADME parameters produced positive results (Table 2). The toxicity parameters were assessed by PROTOX 0.3 (Table 3). Compounds containing nitrogen or oxygen are now essential in the search for novel cancer-fighting medications. More pharmacological research, structure-activity relationship (SAR) analysis, and synthesis are required in order to advance the development of life-saving medicinal chemistry treatments by clarifying their therapeutic potential and validating their effectiveness in treating cancer. ¹⁸

Numerous potential heterocyclic chemical compounds, including pharmaceuticals with oxygen or nitrogen groups that are currently on the market, were successfully identified by this in-silico analysis. These medications showed strong binding affinities to the CDK-2 by co-crystallizing the crystal structure of PDGFRA T674I with crenolanib, with indazole inhibitor nine binding at the CDK-2's active site. The compounds ethyl 2,3-dihydro-1h-indole-2-carboxylate (2s,3r,4r,5s,6r) were identified using PyRX and MZ DOCK docking approaches. [methyl (4-ethoxyphenyl)] -2-[4-chloro-3-] phenyl -6methylsulfanyloxane-3,4,5-triol were found to be important candidates with binding energies that were similar to, and in some cases even closer to, those of the approved standard drug imatinib. The potential bioavailability and drug-likeness of these chosen compounds are indicated by their good Swiss-ADME properties and compliance with Lipinski's Rule. Considering the established function of heterocyclic compounds in the creation of antiviral drugs, our results offer an essential computational basis. Additional pharmacological and structure-activity. Triazoles, pyridines, quinolines, indoles, and thiazoles are examples of heterocyclic scaffolds, which are essential building blocks in medicinal chemistry. Their distinct electrical, lipophilic, and hydrogen-bonding characteristics—which are essential for molecular identification in biological systems—are made possible by their aromatic nature and the presence of heteroatoms (N, O, and S). Tyrosine kinase inhibitor imatinib (Gleevec) was created using a heteroaromatic pharmacophore (pyrimidine and piperazine rings); therefore, evaluating novel heteroaromatic scaffolds against it offers a logical standard for anticancer efficacy.